Clinical trial
A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis
NCT07020715
Study timeline
Study start (estimated)2026-07-01Date precision: day
Registry last updated2026-05-05
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Multiple Sclerosisunresolved
Interventions
Tolerogenic dendritic cells (tolDC)BIOLOGICAL
Sponsors & collaborators
University Hospital, Antwerplead sponsor
Fundació Institut Germans Trias i Pujolcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT07020715 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.